NO20022971L - Butynediol derivatives - Google Patents

Butynediol derivatives

Info

Publication number
NO20022971L
NO20022971L NO20022971A NO20022971A NO20022971L NO 20022971 L NO20022971 L NO 20022971L NO 20022971 A NO20022971 A NO 20022971A NO 20022971 A NO20022971 A NO 20022971A NO 20022971 L NO20022971 L NO 20022971L
Authority
NO
Norway
Prior art keywords
butynediol
derivatives
compounds
preparation
general formula
Prior art date
Application number
NO20022971A
Other languages
Norwegian (no)
Other versions
NO20022971D0 (en
Inventor
Martin Bolli
Christoph Boss
Martine Clozel
Walter Fischli
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of NO20022971L publication Critical patent/NO20022971L/en
Publication of NO20022971D0 publication Critical patent/NO20022971D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

Foreliggende oppfinnelse angår nye butyndiol-derivater med den generelle formel I og anvendelse av dem som aktive bestanddeler ved fremstilling av farmasøytiske preparater. Oppfinnelsen angår også beslektede aspekter omfattende fremgangsmåter for fremstilling av forbindelsene, farmasøytiske preparater inneholdende én eller flere forbindelser med den generelle formel I og spesielt anvendelse av dem som endotelin-reseptorantagonister.The present invention relates to novel butynediol derivatives of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also relates to related aspects comprising processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula I and in particular their use as endothelin receptor antagonists.

NO20022971A 1999-12-22 2002-06-20 Butynediol derivatives NO20022971D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP9910276 1999-12-22
PCT/EP2000/012743 WO2001046156A1 (en) 1999-12-22 2000-12-14 Butyne diol derivatives

Publications (2)

Publication Number Publication Date
NO20022971L true NO20022971L (en) 2002-06-20
NO20022971D0 NO20022971D0 (en) 2002-06-20

Family

ID=8167542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022971A NO20022971D0 (en) 1999-12-22 2002-06-20 Butynediol derivatives

Country Status (12)

Country Link
JP (1) JP2003518102A (en)
KR (1) KR20020068373A (en)
CN (1) CN1407973A (en)
AU (1) AU3536701A (en)
BR (1) BR0016241A (en)
CA (1) CA2389479A1 (en)
HU (1) HUP0204168A2 (en)
IL (1) IL149529A0 (en)
MX (1) MXPA02006250A (en)
NO (1) NO20022971D0 (en)
WO (1) WO2001046156A1 (en)
ZA (1) ZA200203796B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001263850A1 (en) * 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
BRPI0116237B8 (en) 2000-12-18 2021-05-25 Actelion Pharmaceuticals Ltd "sulfamide compound, pharmaceutical composition containing it and its use as an endothelin receptor antagonist drug".
DE602005021641D1 (en) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab NEW DISUBSTITUTED PHENYLPIPERIDINES AND PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION
AR062501A1 (en) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
MX2010001837A (en) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Iron with actively cooled soleplate and method for cooling the soleplate.
US8916385B2 (en) * 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (en) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Benzenesulfonamide derivatives of pyrimidine or their salts, pharmaceutical composition for treatment of diseases associated with endothelin activity
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
TW313568B (en) * 1994-12-20 1997-08-21 Hoffmann La Roche
HUT77307A (en) * 1994-12-20 1998-03-30 F. Hoffmann-La Roche Ag. Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
US5739333A (en) * 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
HUP0000474A3 (en) * 1995-12-20 2001-06-28 Astellas Pharma Inc Chuo Ku Arylethenesulfonamide derivatives and drug composition containing the same
WO1998003488A1 (en) * 1996-07-23 1998-01-29 Shionogi & Co., Ltd. Novel pyrimidine compounds and drug compositions
AU1785599A (en) * 1998-01-19 1999-08-02 Shionogi & Co., Ltd. Novel pyrimidine derivatives

Also Published As

Publication number Publication date
KR20020068373A (en) 2002-08-27
BR0016241A (en) 2002-11-12
IL149529A0 (en) 2002-11-10
MXPA02006250A (en) 2004-09-06
ZA200203796B (en) 2003-10-29
HUP0204168A2 (en) 2003-04-28
NO20022971D0 (en) 2002-06-20
AU3536701A (en) 2001-07-03
WO2001046156A1 (en) 2001-06-28
CA2389479A1 (en) 2001-06-28
CN1407973A (en) 2003-04-02
JP2003518102A (en) 2003-06-03

Similar Documents

Publication Publication Date Title
NO20050932L (en) 1-pyridin-4-yl-urea derivatives
ATE286500T1 (en) 1,2,3,4-TETRAHYDROISOCINOLINE DERIVATIVES
NO20061395L (en) New pyridine derivatives
NO20032905L (en) New benzodiazepines and related heterocyclic derivatives useful as orexin receptor antagonists
NO20051102L (en) Sulfonylamino-acetic acid derivatives
NO20042844L (en) 4- (piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as uprotensin II receptor antagonists
MXPA03004780A (en) Novel sulfamides and their use as endothelin receptor antagonists.
MXPA05010137A (en) Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists.
NO20034230L (en) 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
NO20050668L (en) 7,8,9,10-tetrahydro-6H-azepino6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo [2,1-B] quinazolinone derivatives
NO20050290L (en) Novel tetrahydropyridine derivatives as renin inhibitors
ECSP045378A (en) NEW DIAZABICICLONONENE DERIVATIVES
NO20052520L (en) New sulfamides
ATE383345T1 (en) QUINOXALIN-3-ONE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS.
MXPA04001252A (en) Novel benzo-fused heterocycles as endothelin antagonisits.
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
DK1307445T3 (en) Benzofuran derivatives and their use as antibacterial agents
WO2002008200A3 (en) Arylethene-sulfonamides, their preparation and their use as endothelin antagonists
NO20022971L (en) Butynediol derivatives
DE602004027384D1 (en) BENZOFURANDERIVATES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application